Skip to main content
NewslettersWatchlist
hello world

Provided Content: Content provided by PR Newswire. The Globe and Mail was not involved, and material was not reviewed prior to publication.

INOVIO Announces U.S. FDA Breakthrough Therapy Designation Granted for INO-3107 for the Treatment of Recurrent Respiratory Papillomatosis

PR Newswire - Thu Sep 7, 2023

• Designation based on clinical evidence indicating INO-3107 may demonstrate substantial improvement over existing therapies

• First Breakthrough Therapy designation for an INOVIO DNA medicine candidate

Read more at prnewswire.com

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2024.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).